Patients with type 2 diabetes mellitus (T2DM) who receive weekly dulaglutide are more likely to achieve fasting blood glucose (FBG) ≤6.7mmol/L at 2 weeks than those treated with m…

Objective: To investigate the effects of dulaglutide and non-insulin active comparators on FBG values in patients with T2DM in AWARD-1, -3 and -5. Methods: Exploratory post-hoc, by study analyses were performed to determine the percentage of patients receiving dulaglutide 1.5 mg (n = 852), metformin (n = 268), sitagliptin (n = 315) or exenatide BID (n = 276) with FBG ≤6.7mmol/L at baseline and at 2 and 52 weeks. The odds of reaching FBG ≤6.7mmol/L at week 2 were estimated using logistic regression. Results: At baseline, 22.9%, 10.4% and 11.5% of patients in AWARD-1, -3, and -5, respectively, had FBG ≤6.7mmol/L.…